Genetic predisposition and treatment-related leukemia

Medical and Pediatric Oncology
J P Perentesis

Abstract

Treatment-related leukemias are one of the most devastating late complications of cancer therapy. Patients with rare cancer predisposition syndromes including neurofibromatosis type 1 and inherited p53 mutations are at an increased risk for this complication. Other patients may have increased susceptibility because they possess common genetic polymorphisms in drug-metabolizing enzymes that result in impaired detoxification of chemotherapy or inefficient repair of drug-induced genetic damage. We review studies that have identified a potential role for polymorphisms in the genes encoding the glutathione-S-transferases (GSTs), NAD(P) H: quinone oxidoreductase, myeloperoxidase, N-acetyltransferase (NATs), cytochrome P450 (CYP) 1A1 and 3A4, methylenetetrahydrofolate reductase (MTHFR), cystathionine-beta-synthase (CBS), and others in the etiology of primary or secondary acute leukemias, and therapy-related complications. The identification of high risk polymorphisms and use of pharmacogenetically-guided therapies holds promise to improve the outcome of cancer therapy and reduce the risk of treatment-related leukemias.

References

Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J SeidegårdW R Pearson
Jan 1, 1985·Medical and Pediatric Oncology·L M Secker-WalkerA Todd
May 1, 1983·American Journal of Clinical Pathology·J W VardimanJ Rowley
Mar 1, 1996·Baillière's Clinical Haematology·F E van Leeuwen
Dec 16, 1996·Biochimica Et Biophysica Acta·J Sáez-Valero, C J Vidal
May 17, 1997·Lancet·W AtoyebiJ S Wainscoat
Feb 12, 1998·Proceedings of the National Academy of Sciences of the United States of America·K B GaleM F Greaves
Aug 14, 1998·Environmental Health Perspectives·M T Smith, L Zhang
Aug 27, 1998·Journal of the National Cancer Institute·T R RebbeckS B Malkowicz
Sep 28, 1998·Biochimica Et Biophysica Acta·C A Felix
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·C A FelixT R Rebbeck
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B H KushnerS C Jhanwar
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A SmithD Vena
Jul 8, 1999·Proceedings of the National Academy of Sciences of the United States of America·M T Smith
Jul 8, 1999·Proceedings of the National Academy of Sciences of the United States of America·J L MoranD Ross
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·C F SkibolaG Morgan
Dec 11, 1999·Nucleic Acids Research·E M SmigielskiS T Sherry
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I N MicallefA Z Rohatiner
Apr 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·R StrickJ D Rowley
Jun 16, 2000·Environmental Health Perspectives·C Infante-RivardD Sinnett
Jun 24, 2000·Leukemia·P M CarliM Maynadié
Jul 6, 2000·Cancer Causes & Control : CCC·C Infante-RivardD Sinnett

❮ Previous
Next ❯

Citations

Aug 8, 2008·Bulletin of Experimental Biology and Medicine·T I FominaE A Timina
Apr 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Frank GriesingerDetlef Haase
Oct 20, 2009·Nutrition and Cancer·Daniel PráMichael Fenech
Jun 24, 2006·Journal of Pediatric Hematology/oncology·Kudret CağlarMünevver Büyükpamukçu
Sep 8, 2010·Hematology/oncology Clinics of North America·Jane E Churpek, Kenan Onel
Mar 21, 2007·British Journal of Haematology·Pascual BoluferMiguel-Angel Sanz
Jul 2, 2004·Therapeutic Drug Monitoring·James G Donnelly
Mar 17, 2004·The Pharmacogenomics Journal·V StearnsD A Flockhart
Apr 28, 2004·The Pharmacogenomics Journal·R BuK Bhatia
Mar 19, 2011·Pediatric Hematology and Oncology·Ali Varan, Rejin Kebudi

❮ Previous
Next ❯